The pharmaceutical industry has prepared document with proposals for new Government

The pharmaceutical industry, represented by entities of various segments of the production chain, has prepared a document with the proposals for the new President of Brazil, to be known after the second round of the elections, scheduled for October 28. Among the topics considered are the quality of the central regulatory framework and legal certainty. In the document, the pharmaceutical industry highlights the need for a regulatory agency (Anvisa) swift and unbureaucratic, ensuring safety, efficacy and quality from standards based on health risk analyses, with Board indicated according to criteria technicians laid out in specific legislation. Another issue concerns the restructuring of the National Institute of Industrial Property (Inpi) to readequá it to the size of demand, with recruitment of manpower and adequate training, administrative and financial autonomy, reduction and treatment adequate backlog. The document also lists the price regulation of drugs adequate to the brazilian reality by encouraging innovation and the increased access of the population, including the release of prices where the market auto adjust for the competition. In terms of policies, the industry points to the continuity and improvement of programmes, coordinated by the Ministry of health, for the production of drugs and medicines in Brazil and to the development of new products and technologies. The document cites the expansion of access of the population to medicines, with maintenance and expansion of public programs for the provision of basic medicines of wide access and of high complexity. The industry argues is still the alignment and harmonization of universities with enterprises and institutes, in a coordinated manner with objectives, priorities and long-term projects, with implementation of a plan of action aimed at mapping and clarity of demand technology companies to universities. The pharmaceutical industry asks still encouraging innovation and investment, reducing the tax burden on medicines, feasibility and predictability of funding for research, development, innovation, investments in health sector and bureaucracy of the processes in the organs. Another point is the improvement of rules for conducting clinical research with reduction of instances involved and time limits compatible with the standards of excellence. NúmerosSegundo the document, private industry, international and public laboratories installed in the country produce about 70% of the drugs consumed here. "We employ directly more than 100,000 Brazilians, we export more than $ $1.3 billion per year contributing to the reduction of the deficit of the trade balance and invest in factories and research and development centres around R $20 billion over the last five years ". It also States that sector always interacted and built solutions with the Brazilian State to face immense challenges, such as the eradication of disease through local production of vaccines, Aids epidemic control, expansion of access of the population to generic quality, production of pharmaceuticals, biotechnology and innovative medicines.